Drugs for Mandibular Hypoplasia, Deafness, Progeroid Features, and Lipodystrophy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 135)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ritonavir |
Approved, Investigational |
Phase 4 |
|
155213-67-5 |
392622 |
Synonyms:
538, ABT
A-84538
A-84538|ABBOTT-84538|ABT 538|ABT-538|Norvir®|RTV
Abbott 84538
ABBOTT-84538
ABT 538
ABT-538
|
N-[(1S,3S,4S)-1-BENZYL-3-HYDROXY-5-PHENYL-4-{[(1,3-THIAZOL-5-YLMETHOXY)CARBONYL]AMINO}PENTYL]-N~2~-(METHYL{[2-(1-METHYLETHYL)-1,3-THIAZOL-4-YL]METHYL}CARBAMOYL)-L-VALINAMIDE
Norvir
Norvir Sec
NSC-693184
Ritonavir
RITONAVIR RELATED COMPOUNDS MIXTURE
Ritonavirum
|
|
2 |
|
Amprenavir |
Approved, Investigational |
Phase 4 |
|
161814-49-9 |
65016 |
Synonyms:
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate
(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamic acid
141 W94
141W94
Agenerase
AMP
Amprenavir
Amprénavir
Amprenavirum
|
AMV
APV
Glaxo wellcome brand OF amprenavir
GlaxoSmithKline brand OF amprenavir
J05AE05
KVX-478
Prozei
Tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate
Vertex
Vertex VX478
VX-478
|
|
3 |
|
Enfuvirtide |
Approved, Investigational |
Phase 4 |
|
159519-65-0 |
16130199 |
Synonyms:
ACTYRTHRSERLEUILEHISSERLEUILEGLUGLUSERGLNASNGLNGLNGLULYSASNGLUGLNGLULEULEUGLULEUASPLYSTRPALASERLEUTRPASNTRPPHENH2
AC-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2
DP178
DP-178
Enfuvirtida
ENFUVIRTIDE
ENVELOPE POLYPROTEIN GP160 PRECURSOR [CONTAINS
|
EXTERIOR MEMBRANE GLYCOPROTEIN,GP120, TRANSMEMBRANE GLYCOPROTEIN,GP41]
FUZEON
FUZEON T-20
PENTAFUSIDE
T 20
T20
T-20
|
|
4 |
|
Efavirenz |
Approved, Investigational |
Phase 4 |
|
154598-52-4 |
64139 |
Synonyms:
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-(S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
6-Chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
Bristol-myers squibb brand OF efavirenz
DMP 266
DMP-266
DMP-266|DMP266|EFV|L-743,726|L-743726|Stocrin®|Sustiva®
Du pont brand OF efavirenz
|
Efavirenz
Éfavirenz
Efavirenz, (R)-isomer
Efavirenz, (S)-isomer
Efavirenzum
EFV
Merck sharp and dohme brand OF efavirenz
Stocrin
Sustiva
SUSTIVA 600
United drug brand OF efavirenz
|
|
5 |
|
Nelfinavir |
Approved |
Phase 4 |
|
159989-64-7 |
64143 |
Synonyms:
1UN
AG1343
Agouron brand OF nelfinavir mesylate
Mesylate, nelfinavir
Monomethane sulfonate, nelfinavir
Nelfinavir
Nelfinavir mesylate
|
Nelfinavir monomethane sulfonate
NFV
NLF
Roche brand OF nelfinavir mesylate
Sulfonate, nelfinavir monomethane
Viracept
|
|
6 |
|
Nevirapine |
Approved |
Phase 4 |
|
129618-40-2 |
4463 |
Synonyms:
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO(3,2-B
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
2',3'-E)(1,4)DIAZEPIN-6-ONE
ABBR NVP
BI RG 587
BIRG-0587
BIRG587
BI-RG-587
Hemihydrate, nevirapine
NEV
|
Nevirapina
NEVIRAPINE
NEVIRAPINE ANHYDROUS
Nevirapine hemihydrate
Nevirapine, anhydrous
NSC-641530
NVP
Viramune
VIRAMUNE XR
|
|
7 |
|
Stavudine |
Approved, Investigational |
Phase 4 |
|
3056-17-5 |
18283 |
Synonyms:
1-(2,3-Dideoxy-b-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-(2,3-Dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine
2',3' Didehydro 3' deoxythymidine
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-Didehydro-3'-deoxythymidine
3'-Deoxy-2'-thymidinene
ABBR D4T
BMY-27857
Bristol-myers brand OF stavudine
Bristol-myers squibb brand OF stavudine
d4T
D-4T
|
Estavudina
Estavudina [INN-Spanish]
NSC-163661
Sanilvudine
STAVUDIN
STAVUDINE
Stavudine [Usan:Ban:Inn]
Stavudine, monosodium salt
Stavudinum
Stavudinum [INN-Latin]
STV
Zerit
ZERIT XR
Zerut XR
|
|
8 |
|
Indinavir |
Approved |
Phase 4 |
|
150378-17-9 |
5362440 |
Synonyms:
(1(1S,2R),5(S))-2,3,5-Trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl)-D-erythro-pentonamide
Compound J
Crixivan
INDINAVIR
INDINAVIR ANHYDROUS
INDINAVIR MONOHYDRATE
Indinavir sulfate
|
Indinavir sulphate
INDINAVIR SYSTEM SUITABILITY
Indinavir, sulfate (1:1)
L-735524
MK-639
Sulfate, indinavir
|
|
9 |
|
Didanosine |
Approved |
Phase 4 |
|
69655-05-6 |
50599 |
Synonyms:
2',3' Dideoxyinosine
2,3-Dideoxyinosine
2',3'-Dideoxyinosine
9-((2R,5S)-5-(Hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one
9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol
9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
ABBR ddi
BMY-40900
Bristol myers brand OF didanosine
Bristol myers squibb brand OF didanosine
Bristol-myers brand OF didanosine
Bristol-myers squibb brand OF didanosine
|
DDI
DdI (antiviral)
DdIno
Didanosina
Didanosine
DIDANOSINE SYSTEM SUITABILITY MIXTURE
Didanosinum
Dideoxyinosine
DIDEOXYINOSINE (DDI)
NSC-612049
Videx
VIDEX EC
|
|
10 |
|
Tipranavir |
Approved, Investigational |
Phase 4 |
|
174484-41-4 |
65027 54682461 |
Synonyms:
3'-((1R)-1-((6R)-5,6-DIHYDRO-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-2H-PYRAN-3-YL)PROPYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONANILIDE
APTIVUS
N-{3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3,4-dihydro-2H-pyran-5-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulphonamide
|
|
|
11 |
|
Saquinavir |
Approved, Investigational |
Phase 4 |
|
127779-20-8 |
60787 441243 |
Synonyms:
(2S)-N-[(2S,3R)-4-[(3S)-3-(Tert-butyl-C-hydroxycarbonimidoyl)-decahydroisoquinolin-2-yl]-3-hydroxy-1-phenylbutan-2-yl]-2-[(quinolin-2-yl)formamido]butanediimidate
FORTOVASE
Invirase
Monomethanesulfonate, saquinavir
RO-31-8959
RO-318959000
SAQUINAVIR
|
Saquinavir mesylate
Saquinavir monomethanesulfonate
Saquinivir
SCH-52852
Sequinavir
SQV
|
|
12 |
|
Lopinavir |
Approved |
Phase 4 |
|
192725-17-0 |
92727 |
Synonyms:
378, ABT
A-157378.0
A-157378-0
ABT 378
ABT-378
ABT-378a-157378-0a-157378.0
Aluviran
Kaletra
|
Koletra
LOPINAVIR
LPV
N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
SID124893167
SID144205757
SID50111692
|
|
13 |
|
Pioglitazone |
Approved, Investigational |
Phase 4 |
|
111025-46-8 |
4829 |
Synonyms:
(+-)-5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
(±)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-(4-(2-(5-Ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione
5-{4-[2-(5-ETHYLPYRIDIN-2-YL)ETHOXY]BENZYL}-1,3-THIAZOLIDINE-2,4-DIONE
Actos
Actos®|Glustin®|pioglitazone HCl|U-72107A
Actost
AD-4833
DUETACT
Glustin
Pioglitazona
Pioglitazona [INN-Spanish]
|
PIOGLITAZONE
Pioglitazone [Ban:Inn]
Pioglitazone HCL
Pioglitazone hydrochloride
Pioglitazonum
Pioglitazonum [INN-Latin]
Poglitazone hydrochloride
U-72107
U-72107A
XAB907
ZACTOS
|
|
14 |
|
Zalcitabine |
Approved, Investigational |
Phase 4 |
|
7481-89-2 |
24066 |
Synonyms:
2',3' Dideoxycytidine
2',3'-Dideoxycytidine
4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)-2-TETRAHYDROFURANYL]-2-PYRIMIDINONE
4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]PYRIMIDIN-2-ONE
4-Amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one
4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]PYRIMIDIN-2-ONE
4-AMINO-1-[(2R,5S)-5-METHYLOLTETRAHYDROFURAN-2-YL]PYRIMIDIN-2-ONE
4-AZANYL-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]PYRIMIDIN-2-ONE
DDC
DDC (Antiviral)
DDCYD
|
Dideoxycytidine
DIDEOXYCYTIDINE (DDC)
Hivid
HIVID roche
Hoffman-la roche brand OF zalcitabine
NSC-606170
RO-242027000
RO-24-2027000
RO-242027000/RO-24-2027-000
Roche brand OF zalcitabine
ZALCITABINE
|
|
15 |
|
Metformin |
Approved |
Phase 4 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
16 |
|
Pravastatin |
Approved |
Phase 4 |
|
81093-37-0 |
54687 |
Synonyms:
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoate
(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid
(3R,5R)-7-[(1S,2S,6S,8S,8AR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
3beta-Hydroxycompactin
Apo pravastatin
Apo-pravastatin
Apotex brand OF pravastatin sodium
Aventis brand OF pravastatin sodium
Bristacol
Bristol-myers squibb brand OF pravastatin sodium
C10AA03
Compactin
Elisor
Eptastatin
Esteve brand OF pravastatin sodium
Juste brand OF pravastatin sodium
Lin pravastatin
Lin-pravastatin
Linson pharma brand OF pravastatin sodium
Lipemol
Liplat
Lipostat
Lipostat®|Pravachol®|pravastatin sodium
Mevalothin
Mevalotin
Mevastatin
Mevinolin
Nu pravastatin
Nu-pharma brand OF pravastatin sodium
Nu-pravastatin
|
Oliprevin
Prareduct
Pravachol
Pravacol
Pravaselect
Pravasin
PRAVASTATIN
Pravastatin acid
Pravastatin monosodium salt, (6 beta)-isomer
Pravastatin sodium
Pravastatin sodium salt
Pravastatin tert octylamine salt
Pravastatin tert-octylamine salt
Pravastatin, (6 beta)-isomer
Pravastatina
Pravastatina [Spanish]
Pravastatine
Pravastatine [French]
Pravastatinum
Pravastatinum [Latin]
Pravator
RMS 431
RMS-431
Sankyo brand OF pravastatin sodium
Selectin
Selektine
Selipran
Sodium salt, pravastatin
Squibb brand OF pravastatin sodium
Vasten
|
|
17 |
|
Racivir |
Approved, Investigational |
Phase 4 |
|
143491-57-0, 143491-54-7 |
60877 |
Synonyms:
(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(−)-(2R,5S)-5-FLUORO-1-[2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL]CYTOSINE
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(−)-2'-DEOXY-5-FLUORO-3'-THIACYTIDINE
(-)-b-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-Amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(−)-CIS-4-AMINO-5-FLUORO-1-(2-HYDROXYMETHYL-1,3-OXATHIOLAN-5-YL)-(1H)-PYRIMIDIN-2-ONE
(-)-Emtricitabine
(-)-FTC
(−)-FTC
(-)-Î’-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(−)-Β-2',3'-DIDEOXY-5-FLUORO-3'-THIACYTIDINE
(+/-)-Emtricitabine
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
2'-DEOXY-5-FLUORO-3'THIACYTIDINE
4-Amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
|
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
524W91
524-W-91
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
ABBR FTC
Beta L 2',3' Dideoxy 5 fluoro 3' thiacytidine
beta-L-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
BW-524W91
Coviracil
EMTRICITABIN
EMTRICITABINA
Emtricitabine
EMTRICITABINUM
Emtriva
FTC
FTC-(-)
RCV
|
|
18 |
|
Insulin glulisine |
Approved |
Phase 4 |
|
207748-29-6 |
|
Synonyms:
APIDRA
APIDRA SOLOSTAR
HMR1964
HMR-1964
INS APIDRA
INS APIDRA OPTICLIK
|
INS APIDRA OPTISET
INS APIDRA SOLOSTAR
INSULIN GLULISINE
Insulin Glulisine (recombinant DNA origin)
INSULIN GLULISINE RECOMBINANT
Insulina glulisina
|
|
19 |
|
Zinc cation |
Approved, Experimental, Investigational |
Phase 4 |
|
7440-66-6, 23713-49-7 |
32051 |
Synonyms:
alpha D Mannosidase
alpha D Mannoside mannohydrolase
alpha Mannosidase
alpha Mannosidase b
alpha-D-Mannosidase
alpha-D-Mannoside mannohydrolase
alpha-Mannosidase
alpha-Mannosidase, lysosomal
alpha-Mannosidase, neutral
Dietary zinc
LAMAN
Lysosomal alpha mannosidase
Lysosomal alpha-mannosidase
Mannohydrolase, alpha-D-mannoside
Mannosidase b, alpha
Neutral alpha mannosidase
|
Neutral alpha-mannosidase
Topostin b
Zinc cation
ZINC ion
Zinc ion(2+)
Zinc(2+)
Zinc(II)
Zinc, chelated
Zinc, elemental
Zinc, ion (ZN2+)
zinc|zinc ion
Zincum metallicum
Zn
ZN(2+)
ZN(II)
ZN2+
|
|
20 |
|
Lamivudine |
Approved, Investigational |
Phase 4 |
|
134678-17-4 |
60825 |
Synonyms:
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-2'-Deoxy-3'-thiacytidine
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
3TC
3'-Thia-2',3'-dideoxycytidine
BCH 189
BCH 189, (-)-
BCH-189
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
b-L-2',3'-Dideoxy-3'-thiacytidine
b-L-3'-Thia-2',3'-dideoxycytidine
Epivir
|
EPIVIR-HBV
Epzicom
GR-109714X
Hepitec
HEPTOVIR
LAMIVUDIN
LAMIVUDINA
LAMIVUDINE
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-isomer
LAMIVUDINUM
ZEFFIX
Î’-L-2',3'-dideoxy-3'-thiacytidine
Î’-L-3'-thia-2',3'-dideoxycytidine
|
|
21 |
|
Abacavir |
Approved, Investigational |
Phase 4 |
|
136470-78-5, 188062-50-2 |
441300 |
Synonyms:
(1S,4R)-4-(2-Amino-6-(cyclopropylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol
{(1S-cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol
ABACAVIR
Abacavir succinate
Abacavir sulfate
ABC
|
ATC CODE J05AF06
ATCVET CODE QJ05AF06
C14H18N6O
EPZICOM
Ziagen
|
|
22 |
|
Zidovudine |
Approved |
Phase 4 |
|
30516-87-1 |
35370 |
Synonyms:
3' Azido 2',3' dideoxythymidine
3' Azido 3' deoxythymidine
3'-Azido-2',3'-dideoxythymidine
3'-Azido-3'-deoxythymidine
Antiviral azt
Apo-Zidovudine
Azidothymidine
AZT
AZT (antiviral)
AZT antiviral
AZT, antiviral
Aztec
BW a509U
BWA 509u
BWA509u
|
BWA-509u
BW-A509U
BW-A-509U
COMPOUND S
COMPOUND-S
Novo-Azt
NSC-602670
Retrovir
ZDV
Zidovudin
Zidovudina
Zidovudine
Zidovudine EP III
Zidovudinum
|
|
23 |
|
Cobicistat |
Approved |
Phase 4 |
|
1004316-88-4 |
24950485 25151504 |
Synonyms:
1,3-THIAZOL-5-YLMETHYL [(2R,5R)-5-{[(2S)-2-({[(2-ISOPROPYL-1,3-THIAZOL-4-YL)METHYL](METHYL)CARBAMOYL}AMINO)-4-(MORPHOLIN-4-YL)BUTANOYL]AMINO}-1,6-DIPHENYLHEXAN-2-YL]CARBAMATE
COBICISTAT
GS 9350
|
GS-9350
N-[5-({hydroxy[(1,3-thiazol-5-yl)methoxy]methylidene}amino)-1,6-diphenylhexan-2-yl]-2-(N-methyl-N-{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}-(C-hydroxycarbonimidoyl)amino)-4-(morpholin-4-yl)butanimidate
TYBOST
|
|
24 |
|
Rilpivirine |
Approved |
Phase 4 |
|
500287-72-9 |
6451164 |
Synonyms:
278, TMC
4-{[4-({4-[(e)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile
EDURANT
HCL, Rilpivirine
Hydrochloride, rilpivirine
R-278474
Rilpivirina
|
RILPIVIRINE
Rilpivirine HCL
Rilpivirine hydrochloride
TMC 278
TMC278
TMC-278
|
|
25 |
|
Darunavir |
Approved |
Phase 4 |
|
635728-49-3, 206361-99-1 |
213039 |
Synonyms:
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamic acid
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulphanilamido)propyl)carbamate
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulphanilamido)propyl)carbamic acid
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamATE
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamic acid
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulphonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate
(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulphonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamic acid
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamic acid
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulphonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulphonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamic acid
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamic acid
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulphonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate
(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulphonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamic acid
[(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamate (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
[(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
[(S)-3-[(4-Amino-benzenesulphonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamate (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
[(S)-3-[(4-Amino-benzenesulphonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
|
{(1S,2R)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamate (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
{(1S,2R)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
{(1S,2R)-3-[(4-amino-benzenesulphonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamate (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
{(1S,2R)-3-[(4-amino-benzenesulphonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester
114, TMC
AIDS073035
DARUNAVIR
Darunavir ethanolate
Darunavirum
Darunavirum [INN-latin]
Ethanolate, darunavir
MC-114
N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide
N-((1S,2R)-3-(((4-Aminophenyl)sulphonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide
Prezista
TMC 114
TMC114
TMC-114
TMC-41629
UIC-94017
UIC-940T
|
|
26 |
|
Dolutegravir |
Approved |
Phase 4 |
|
1051375-16-6 |
57414794 54726191 |
Synonyms:
DOLUTEGRAVIR
GSK 1349572
GSK1349572
GSK-1349572
|
S/GSK1349572
S-349572
TIVICAY
|
|
27 |
|
Sorbitol |
Approved, Investigational |
Phase 4 |
|
69-65-8, 50-70-4 |
453 6251 5780 |
Synonyms:
(-)-Sorbitol
(−)-SORBITOL
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5S)-Hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
7B5697N
ALEXITOL SODIUM
ARIDOL KIT
Baxter brand OF sorbitol
Bronchitol
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-(-)-Sorbitol
D-(−)-SORBITOL
D-Glucitol
Diakarmon
Diosmol
D-Mannitol
D-Sorbit
D-SORBITOL
D-Sorbol
Dulcite
e 420
e 421
e420
e-420
e421
e-421
Esasorb
FEMA NO. 3029
Foodol D 70
FRAXININE
GLC-Ol
Glucarine
Glucitol
g-Ol
Hexahydroxyhexane
Hexanhexol
INS NO.421
INS-421
Invenex
ISOMALT IMPURITY, MANNITOL-
ISOMALT IMPURITY, SORBITOL-
Isotol
Karion
Karion instant
Klysma sorbit
Kyowa powder 50m
L-Gulitol
Manicol
MANITOL
Maniton S
Maniton-S
Manna sugar
Mannazucker
Mannidex
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
MANNITOLUM
|
Mannogem 2080
Marine crystal
Medefield brand OF sorbitol
Medevac
Multitol
Mushroom sugar
Neosorb
Neosorb 20/60dC
Neosorb 70/02
Neosorb 70/70
Neosorb p 20/60
Neosorb p 60
Neosorb p 60W
Nivitin
NSC-25944
NSC-407017
Osmitrol
Osmofundin
Osmosal
Pfizer brand OF sorbitol
Resectisol
Resulax
SDM No. 35
Sionit
Sionit K
Sionite
Sionon
Siosan
Sorbex m
Sorbex R
Sorbex RP
Sorbex S
Sorbex X
Sorbilande
Sorbilax
Sorbit
Sorbit D 70
Sorbit DP
Sorbit DP 50
Sorbit D-powder
Sorbit kyowa powder 50m
Sorbit L 70
Sorbit S
Sorbit T 70
Sorbit W 70
Sorbit WP
Sorbit W-powder
Sorbit W-powder 50
Sorbite
SORBITOL
Sorbitol 3% in plastic container
Sorbitol F
Sorbitol FK
Sorbitol FP
Sorbitol pfizer brand
Sorbitol S
Sorbitol syrup C
Sorbitur
Sorbo
Sorbogem 712
Sorbol
Sorbostyl
Tobrex
Trommsdorff brand OF sorbitol
Yal
|
|
28 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
29 |
|
Thiamine |
Approved, Investigational, Nutraceutical, Vet_approved |
Phase 4 |
|
70-16-6 |
1130 |
Synonyms:
[<sup>3</sup>H]-thiamine|[<sup>3</sup>H]vitamin B<sub>1</sub>
2-[3-[(4-AMINO-2-METHYL-PYRIMIDIN-5-YL)METHYL]-4-METHYL-1-THIA-3-AZONIACYCLOPENTA-2,4-DIEN-5-YL]ETHANOL
2-[3-[(4-AMINO-2-METHYL-PYRIMIDIN-5-YL)METHYL]-4-METHYL-THIAZOL-5-YL]ETHANOL
3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM
ANEURIN
ANTIBERIBERI FACTOR
APATE DROPS
BEATINE
BEDOME
BEGIOLAN
BENERVA
BEQUIN
BERIN
BETALIN S
BETAXIN
BETHIAZINE
BEUION
BEVITEX
BEVITINE
BEWON
BIAMINE
BITHIAMIN
BIUNO
BIVATIN
BIVITA
CERNEVIT-12
CLOTIAMINA
ESKAPEN
|
ESKAPHEN
HYBEE
LIXA-BETA
METABOLIN
Mononitrate, thiamine
SLOWTEN
THD
THIADOXINE
THIAMIN
THIAMINAL
THIAMINE
Thiamine mononitrate
THIAMINE(1+)
THIAMINE(1+) ION
THIAMINIUM
Thiaminum
THIAMOL
THIAVIT
TIAMIDON
TIAMINA
TIAMINAL
TROPHITE
VETALIN S
VIB
VINOTHIAM
VITAMIN B 1
VITAMIN B1
VITANEURON
|
|
30 |
|
Riboflavin |
Approved, Investigational, Nutraceutical, Vet_approved |
Phase 4 |
|
83-88-5 |
493570 |
Synonyms:
(-)-Riboflavin
1-Deoxy-1-(3,4-dihydro-7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10(2H)-yl)-D-ribitol
1-Deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)pentitol
6,7-Dimethyl-9-D-ribitylisoalloxazine
6,7-Dimethyl-9-ribitylisoalloxazine
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)benzo[g]pteridine-2,4(3H,10H)-dione
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)-benzo[g]pteridine-2,4(3H,10H)-dione
7,8-Dimethyl-10-(D-ribo-2,3,4,5-tetrahydroxypentyl)isoalloxazine
7,8-DIMETHYL-10-[(2S,3S,4R)-2,3,4,5-TETRAHYDROXYPENTYL]-2H,3H,4H,10H-BENZO[G]PTERIDINE-2,4-DIONE
7,8-Dimethyl-10-ribitylisoalloxazine
Beflavin
Beflavine
Benzo[g]pteridine riboflavin deriv.
Bisulase
e 101
e101
E-B2
Flavaxin
Flavin BB
Flaxain
FOOD Yellow 15
FREEDA
Hyre
INS NO. 101(I)
Lactobene
|
Lactoflavin
Lactoflavine
NCI-0033298
NSC-33298
Ribipca
Ribocrisina
Riboderm
Riboflavin
RIBOFLAVIN (VIT B2)
RIBOFLAVIN TETRABUTYRATE
Riboflavina
RIBOFLAVINE
Riboflavinum
Ribosyn
Ribotone
Ribovel
Russupteridine yellow III
San yellow b
Vitaflavine
Vitamin b 2
Vitamin b2
Vitamin Bi
Vitamin g
Vitasan b2
|
|
31 |
|
(3-Carboxy-2-(R)-Hydroxy-Propyl)-Trimethyl-Ammonium |
Experimental |
Phase 4 |
|
461-06-3 |
|
Synonyms:
CARNITINE
CARNITINE CHLORIDE
|
|
|
32 |
|
Tenofovir |
Experimental, Investigational |
Phase 4 |
|
147127-20-6, 202138-50-9 |
464205 6398764 |
Synonyms:
(E)-but-2-enedioic acid
(R)-9-(2-PHOSPHONOMETHOXYPROPYL)ADENINE
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-PMPA
[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate
9-(2-Phosphonomethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine
9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer
9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098
9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer
9-PMPA (tenofovir)
Anh. tenofovir
Anhydrous tenofovir
Apropovir
ATRIPLA
bis({[(propan-2-yloxy)carbonyl]oxy}methyl) ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonate (2E)-but-2-enedioate
D,L-Tenofovir
|
Disoproxil fumarate, tenofovir
Disoproxil, tenofovir
Fumarate, tenofovir disoproxil
GS-1275
GS-1278
PMPA
PMP-A
TDF
Tenofovir
Tenofovir (anh.)
Tenofovir (anhydrous)
Tenofovir anhydrous
Tenofovir disoproxil
Tenofovir disoproxil fumarate
TRUVADA
Viread
|
|
33 |
|
Atazanavir Sulfate |
|
Phase 4 |
|
|
|
34 |
|
Insulin, Globin Zinc |
|
Phase 4 |
|
|
|
35 |
|
Insulin |
|
Phase 4 |
|
|
|
Synonyms:
AFREZZA
EXUBERA
HUMULIN
HUMULIN BR
HUMULIN R
HUMULIN R KWIKPEN
HUMULIN R PEN
INS HUMULIN R
INSULIN
INSULIN (HUMAN)
INSULIN BOVINE
INSULIN BOVINE INSULIN
|
INSULIN HUMAN
INSULIN HUMAN (BIOSYNTHESIS)
INSULIN HUMAN (SYNTHESIS)
INSULIN RECOMBINANT HUMAN
INSULIN RECOMBINANT PURIFIED HUMAN
INSUMAN INFUSAT
MYXREDLIN
NOVOLIN
NOVOLIN R
VELOSULIN
VELOSULIN BR
VELOSULIN BR HUMAN
|
|
36 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
37 |
|
Anti-Bacterial Agents |
|
Phase 4 |
|
|
|
38 |
|
Antitubercular Agents |
|
Phase 4 |
|
|
|
39 |
|
Antibiotics, Antitubercular |
|
Phase 4 |
|
|
|
40 |
|
Hypoglycemic Agents |
|
Phase 4 |
|
|
|
41 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
42 |
|
Hypolipidemic Agents |
|
Phase 4 |
|
|
|
43 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 4 |
|
|
|
44 |
|
Lipid Regulating Agents |
|
Phase 4 |
|
|
|
45 |
|
Vitamins |
|
Phase 4 |
|
|
|
46 |
|
Folate |
|
Phase 4 |
|
|
|
47 |
|
Vitamin B9 |
|
Phase 4 |
|
|
|
48 |
|
Trace Elements |
|
Phase 4 |
|
|
|
49 |
|
Vitamin B Complex |
|
Phase 4 |
|
|
|
50 |
|
Micronutrients |
|
Phase 4 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 166)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) |
Unknown status |
NCT00122226 |
Phase 4 |
Lopinavir/ritonavir + zidovudine + lamivudine;Lopinavir/ritonavir + nevirapine |
2 |
Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in Patients With HIV. Influence on Morphological and Metabolic Disorders. A Randomized, Open-Label Multicenter Trial. |
Unknown status |
NCT00135460 |
Phase 4 |
nucleoside analogue sparing HAART regimen |
3 |
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks |
Unknown status |
NCT00426296 |
Phase 4 |
atazanavir (Reyataz);ritonavir (Norvir) |
4 |
A Phase IV, Open-Label, Randomized, Multicenter Trial Assessing a Reyataz-Based Substitution Approach in the Management of Lipodystrophy Syndrome. Research Into Atazanavir in Lipodystrophy (The REAL Study) |
Completed |
NCT00135356 |
Phase 4 |
Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs);continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs) |
5 |
Comparison of Strategies of Interruption/Reinitiation of Antiretroviral Therapy in Response to Immunologic/Virologic Changes in HIV-Infected Patients With Lipodystrophy. |
Completed |
NCT00646984 |
Phase 4 |
Standard continuous antiretroviral therapy;CD-4 guided therapy interruption;Viral load driven treatment interruption |
6 |
Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time |
Completed |
NCT00192660 |
Phase 4 |
Lamivudine;Stavudine;Didanosine;Zidovudine;Tenofovir;Abacavir;Efavirenz (EFV);Nevirapine;Indinavir;Saquinavir;Amprenavir;Ritonavir;Nelfinavir;Tipranavir;enfuvirtide (T20) |
7 |
Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Influence on Metabolic Abnormalities |
Completed |
NCT00139178 |
Phase 4 |
Different HAART regimens |
8 |
Mecahnisms of Lipodystrophy in HIV-Infected Patients |
Completed |
NCT00457665 |
Phase 4 |
Nelfinavir;Efavirenz |
9 |
Glaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL) |
Completed |
NCT00005764 |
Phase 4 |
Lamivudine/Zidovudine;Abacavir sulfate;Lamivudine |
10 |
The Study of Mechanisms of Lipodystrophy in HIV-Infected Patients |
Completed |
NCT00006190 |
Phase 4 |
Nelfinavir mesylate;Stavudine;Lamivudine;Efavirenz |
11 |
A Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/Ritonavir |
Completed |
NCT00865007 |
Phase 4 |
Monotherapy (Lopinavir/ritonavir);Monotherapy (Lopinavir/ritonavir) + ABC/3TC |
12 |
A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism |
Completed |
NCT00192621 |
Phase 4 |
Combivir (zidovudine [AZT] / lamivudine [3TC]);Kaletra (lopinavir [LPVr]) |
13 |
The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients on Highly Active Antiretroviral Therapy (HAART) |
Completed |
NCT00119769 |
Phase 4 |
Placebo;Genotropin (human recombinant Growth hormone) |
14 |
Metabolic Abnormalities in HIV-infected Persons |
Completed |
NCT01612858 |
Phase 4 |
Metformin;Pioglitazone |
15 |
Yoga for the Management of HIV-Metabolic Syndromes |
Completed |
NCT00627380 |
Phase 4 |
|
16 |
A Randomised, Double-Blind Study of Pravastatin for the Treatment of Hyperlipidaemia in Patients With HIV |
Completed |
NCT00227500 |
Phase 4 |
Pravastatin |
17 |
Lactic Acid Metabolism in HIV-Infected Persons. Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation. |
Completed |
NCT00202228 |
Phase 4 |
cofactor supplementation (thiamine, riboflavin, L-carnitine) |
18 |
CT to Assess the Effect on the Subcutaneous Fat of Change of EFV for LPV/r in HIV-infected Patients Who Developed Lipoatrophy and Remains Despite Treatment With Efavirenz and Fixed-dose Combination of no Thymidine Nucleoside Analogues. |
Completed |
NCT00978237 |
Phase 4 |
EFV;LPV/r |
19 |
Lipoatrophy in Children, Adolescents and Adults With Modern Treatment Modalities: is There a Beneficial Effect of Insulin Glulisine? |
Completed |
NCT02914886 |
Phase 4 |
Apidra;current insulin |
20 |
Contribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIV |
Recruiting |
NCT04340388 |
Phase 4 |
Dolutegravir 50 MG;Antiretroviral/Anti HIV |
21 |
Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin Therapy |
Recruiting |
NCT03226821 |
Phase 4 |
Tesamorelin |
22 |
A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized Lipodystrophy |
Recruiting |
NCT04026178 |
Phase 4 |
Metreleptin |
23 |
Changes in Weight After Switch to Dolutegravir/Lamivudine or Doravirine/Tenofovir/Lamivudine Compared to Continued Treatment With Dolutegravir/Tenofovir/Lamivudine for Virologically Suppressed HIV Infection. AVERTAS-2 |
Recruiting |
NCT04903847 |
Phase 4 |
Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO];Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] |
24 |
Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1 |
Recruiting |
NCT04904406 |
Phase 4 |
Dolutegravir / Lamivudine Oral Tablet |
25 |
Randomized Comparative Study Evaluating the Rate of Occurrence of a Lipoatrophy Syndrome in ARVnaive HIV-1 Infected Patients Receiving NRTI-Sparing Antiretroviral Regimen (Hippocampe - ANRS 121) |
Terminated |
NCT00122668 |
Phase 4 |
non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitor |
26 |
A Randomized Prospective Study Evaluating the Impact on Fat Distribution of NRTI-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy ANRS 108 NONUKE Study |
Terminated |
NCT00122655 |
Phase 4 |
non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitors |
27 |
A Multi-Centre, Open-Label, Randomised Study to Assess the Efficacy, Durability and Safety of Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy (FLASH) |
Terminated |
NCT00126308 |
Phase 4 |
|
28 |
A Phase IV, Prospective, Non-Blinded, Non-Randomized, Single-Center Clinical Trial to Determine the Longevity, Duration, and Volume-Correcting Efficacy of Sculptraâ„¢ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy |
Withdrawn |
NCT00360139 |
Phase 4 |
|
29 |
Effects of an Exercise Program on Metabolic Parameters of Patients With a HIV Infection. |
Unknown status |
NCT00910936 |
Phase 2, Phase 3 |
|
30 |
Double-Blind, Placebo-Controlled Trial of Leptin Replacement Therapy in Patients With Lipodystrophy |
Completed |
NCT00896298 |
Phase 2, Phase 3 |
Leptin;Placebo |
31 |
Randomized, Comparative, Multicenter, Patient-blinded Trial of the Safety and Efficacy of Intradermal Injections of Polylactic Acid (Newfill TM) Versus Polyacrylamid Gel (Eutrophill) in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE |
Completed |
NCT00383734 |
Phase 3 |
|
32 |
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS |
Completed |
NCT00082628 |
Phase 3 |
Placebo;Serostim® 4 mg;Serostim® 2 mg |
33 |
A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of a 2 mg Dose of TH9507, a Growth Hormone Releasing Factor Analog, in HIV Patients With Excess of Abdominal Fat Accumulation |
Completed |
NCT00123253 |
Phase 3 |
TH9507 |
34 |
Open Label, Multicenter, Single Arm Trial of the Safety and Efficacy of Polyacrylamide Hydrogel Injection in the Management of Human Immunodeficiency Virus-Related Facial Lipoatrophy : THE LIPOPHILL TRIAL |
Completed |
NCT01077765 |
Phase 3 |
|
35 |
A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat Accumulation |
Completed |
NCT00608023 |
Phase 3 |
Tesamorelin;Placebo for Tesamorelin |
36 |
A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects With Lipid Abnormalities |
Completed |
NCT00006412 |
Phase 3 |
Pravastatin sodium;Fenofibrate |
37 |
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Trial of Uridine Supplementation in HIV Lipoatrophy |
Completed |
NCT00307164 |
Phase 2, Phase 3 |
NucleomaxX;NucleomaxX placebo |
38 |
Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized Lipodystrophy |
Recruiting |
NCT02262832 |
Phase 3 |
Metreleptin |
39 |
A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy |
Recruiting |
NCT05164341 |
Phase 3 |
metreleptin;Placebo |
40 |
A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS |
Active, not recruiting |
NCT04517253 |
Phase 2, Phase 3 |
Baricitinib |
41 |
A Multicenter, Open-label, Single-arm, Extension Study With Regard to the Safety and Efficacy of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance (EMPIRE-02) |
Active, not recruiting |
NCT04221152 |
Phase 3 |
Empagliflozin Tablets |
42 |
A Multicenter, Open-label, Single-arm Study With Regard to the Efficacy and Safety of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance |
Active, not recruiting |
NCT04018365 |
Phase 3 |
Empagliflozin Tablets |
43 |
Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in People Living With HIV. |
Not yet recruiting |
NCT04860063 |
Phase 3 |
Berberine;Placebo |
44 |
A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study |
Terminated |
NCT00148850 |
Phase 3 |
Pioglitazone |
45 |
A Randomized, Double-Blind, Placebo-Controlled, With an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy |
Terminated |
NCT02527343 |
Phase 2, Phase 3 |
volanesorsen;Placebo |
46 |
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Recombinant Human Leptin (METRELEPTIN) in Various Forms of Partial Lipodystrophy |
Completed |
NCT02654977 |
Phase 2 |
Metreleptin |
47 |
Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Recombinant Human Growth Hormone and/or Rosiglitazone in the Treatment of Human Immunodeficiency Virus-Associated Visceral Adiposity and Insulin Resistance |
Completed |
NCT00130286 |
Phase 1, Phase 2 |
Rosiglitazone;Recombinant human growth hormone + rosiglitazone |
48 |
An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy |
Completed |
NCT03514420 |
Phase 2 |
AKCEA-ANGPTL3-LRx |
49 |
An Investigator-Initiated Open-Label, Randomized Study of Gemcabene in Adults With Familial Partial Lipodystrophy Disease (FPLD) |
Completed |
NCT03508687 |
Phase 1, Phase 2 |
300mg Gemcabene;600mg Gemcabene |
50 |
Therapeutic Approaches to HAART-Induced Lipodystrophy |
Completed |
NCT00461552 |
Phase 2 |
Leptin |
Search
NIH Clinical Center
for Mandibular Hypoplasia, Deafness, Progeroid Features, and Lipodystrophy Syndrome
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|